Home Pharmaceuticals Global Osteoporosis Drugs Market Size, Share, Growth by 2033

Osteoporosis Drugs Market Size & Outlook, 2025-2033

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others), By Route of Administration (Oral, Injectable) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH54591DR
Last Updated: Sep, 2025
Pages: 110
Author: Mitiksha Koul
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Osteoporosis Drugs Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Bisphosphonates
        1. By Value
      3. Selective Estrogen Inhibitors Modulator (SERM)
        1. By Value
      4. Parathyroid Hormone Therapy
        1. By Value
      5. Calcitonin
        1. By Value
      6. Rank Ligand Inhibitors
        1. By Value
      7. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectable
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Bisphosphonates
          1. By Value
        3. Selective Estrogen Inhibitors Modulator (SERM)
          1. By Value
        4. Parathyroid Hormone Therapy
          1. By Value
        5. Calcitonin
          1. By Value
        6. Rank Ligand Inhibitors
          1. By Value
        7. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectable
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Osteoporosis Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Amgen Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Eli Lilly and Company
    3. F. Hoffmann-La Roche Ltd.
    4. Radius Health Inc.
    5. Merck & Co., Inc.
    6. Novartis AG
    7. Pfizer Inc.
    8. Sun Pharmaceutical Industries Ltd.
    9. Takeda Pharmaceutical Company Limited
    10. Teva Pharmaceutical Industries Ltd.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.